Immatics
gen melanoma as first indication for pivotal development cohort a | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
16 of 75
Related slides by other companies
Alkermes
Investor Day
March 2021
artistry in combination with responses in heavily treated ovarian cancer tumor type line of therapy artistry part efficacy ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer evaluation of evaluation of evaluation of evaluation of ongoing out of patients with scans patients experienced an objective response confirmed and unconfirmed patients remain on study as of march data cut time on study weeks intravenous progressive disease partial response stable disease complete response data cut off march alkermes | Alkermes
TCR2 Therapeutics
Results
September 2022
patient platinum refractory ovarian cancer | TCR2 Therapeutics
Alkermes
Investor Presentation
October 2023
complete response in year old patient with platinum resistant ovarian cancer | Alkermes
Erasca
Investor Presentation
August 2023
eras phase responses observed in patients with ras and alterations in diverse tumor types with single agent schedule | Erasca
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights